Therapeutic Area Specialization Guide: How Hub and SP Workflows Differ by Disease

Thesis

The buyer thesis is to match the vendor to the therapeutic archetype before comparing features or price. A low-caseload rare disease hub, high-volume GLP-1 access engine, oncology buy-and-bill reimbursement team, and CGT orchestration partner should not be scored with the same weights. The cost of a mismatch is delayed therapy, avoidable abandonment, weak data capture, or channel conflict in the exact workflow that determines launch success.

Why This Matters

Manufacturers frequently evaluate hub services and specialty pharmacy vendors using generic criteria — call center capacity, technology platform, pricing model. But the operational reality is that hub workflows, clinical support requirements, pharmacy handling, and payer dynamics differ fundamentally across therapeutic areas. A vendor that excels at autoimmune biologics may struggle with rare disease launches. A specialty pharmacy optimized for oncology may lack the ultra-cold infrastructure for gene therapy.

This guide maps the key differences across five major therapeutic archetypes and identifies which vendor capabilities matter most for each.

---

Five Therapeutic Archetypes

1. Oncology (Including Immuno-Oncology)

Access complexity: High

Dimension	Oncology-Specific Requirements
Administration	Predominantly buy-and-bill (provider-administered IV infusion) for monoclonal antibodies; oral oncolytics growing (25%+ of new approvals)
Reimbursement	Medical benefit (Part B) for infusables; pharmacy benefit (Part D) for oral; J-code management critical; ASP-based reimbursement creates margin pressure
Prior authorization	Complex clinical criteria (biomarker testing, sequencing, prior therapy failure); peer-to-peer reviews common; appeals rate 30%+
Hub services	Buy-and-bill reimbursement support, claims denial management, coding/billing assistance for providers, site-of-care coordination
Specialty pharmacy	Oral oncology dispensing with adherence monitoring; infusion pharmacy (Coram, Option Care Health) for hospital-at-home; LDD networks for novel agents
Clinical support	Side effect management for immunotherapy AEs (immune-related adverse events require multidisciplinary coordination); dose modification tracking; survivorship care
Time sensitivity	Extremely high — treatment delays in oncology directly affect clinical outcomes; time-to-therapy is the critical KPI

Vendor implications:

• Hub vendors need strong buy-and-bill reimbursement teams (ConnectiveRx’s B&B segment represents 46% of revenue)
• Specialty pharmacies need oncology-specific clinical pharmacist teams (Accredo operates a dedicated oncology TRC; BrightSpring’s Onco360)
• Site-of-care optimization capability is critical — PBMs are steering infusion from hospital outpatient to lower-cost settings
• Providers (not patients) are the primary customer of the hub in oncology

2. Rare Disease & Orphan Drugs

Access complexity: Very High

Dimension	Rare Disease-Specific Requirements
Administration	Varies widely: IV infusion, subcutaneous injection, oral, intrathecal, gene therapy; many require specialized administration settings
Reimbursement	High list prices ($100K-$3M+) with complex prior authorization; manufacturer copay programs essential; compassionate use/expanded access common pre-approval
Prior authorization	Diagnosis-specific (genetic testing, enzyme assays, clinical markers); very small patient populations mean payer unfamiliarity with clinical criteria
Hub services	Intensive case management (1 case manager per 20-50 patients vs. 1:200+ for large brands); patient finding/identification; caregiver support; travel coordination
Specialty pharmacy	Ultra-specialized handling; REMS compliance; patient registries; direct-to-patient distribution; limited distribution networks (often 1-5 pharmacies)
Clinical support	Disease education (patients may never have met another patient with their condition); injection/infusion training; clinical monitoring protocols specific to rare disease
Time sensitivity	Variable — some rare diseases are progressive and urgent; others are chronic with less immediate time pressure; gene therapy “one-shot” dosing creates unique urgency

Vendor implications:

• PANTHERx Rare (241-line wiki profile) is the gold standard for rare disease SP — CEO thesis: “rare disease pharmacy is fundamentally different from specialty pharmacy”
• Hub vendors must offer high-touch, low-caseload models incompatible with volume-driven hub economics
• Patient finding services (identifying undiagnosed patients through claims/EHR analytics) are uniquely valuable in rare disease
• Gene therapy launches require SP capabilities that don’t exist at scale: chain-of-identity tracking, REMS coordination, one-time-dose logistics
• REMS programs (300+ active) disproportionately affect rare disease therapies and require dedicated compliance infrastructure

3. Autoimmune & Inflammatory (Including Biosimilar Competition)

Access complexity: Medium-High

Dimension	Autoimmune-Specific Requirements
Administration	Self-administered subcutaneous injection (adalimumab, etanercept, ustekinumab) or IV infusion (infliximab, tocilizumab); patient self-injection training essential
Reimbursement	Pharmacy benefit for SC drugs; medical benefit for IV drugs; biosimilar competition creating formulary volatility; PBM biosimilar mandates increasing
Prior authorization	Step therapy common (fail-first through less expensive biologics); biomarker and diagnosis verification; renewal PA every 6-12 months
Hub services	Copay assistance (high patient cost-sharing), injection training, refill management, formulary switch support (biosimilar transitions), adherence monitoring
Specialty pharmacy	High-volume dispensing with cold chain; injection training and device support; biosimilar substitution management; adherence programs
Clinical support	Self-injection training (auto-injector, prefilled syringe); side effect monitoring (infection screening, TB testing); dose titration support
Time sensitivity	Moderate — autoimmune conditions are chronic; initial access matters but ongoing adherence and refill management are more critical than speed-to-first-dose

Vendor implications:

• Highest-volume hub services category — most large hub vendors (ConnectiveRx, EVERSANA, AssistRx) have deep autoimmune experience
• Biosimilar competition is the defining dynamic: PBM mandates (CVS Cordavis Hyrimoz, Express Scripts biosimilars) are displacing brand manufacturer hub programs
• Copay accumulator/maximizer exposure is highest in autoimmune (high patient volume, high commercial plan coverage)
• Manufacturers facing biosimilar entry need hub vendors that can manage formulary defense, switch-back programs, and patient retention
• Hub economics are most favorable in autoimmune: large patient populations, predictable refill patterns, manageable clinical complexity

4. GLP-1 / Metabolic

Access complexity: High (access crisis)

Dimension	GLP-1-Specific Requirements
Administration	Self-administered subcutaneous injection (semaglutide, tirzepatide); increasingly oral formulations (oral semaglutide)
Reimbursement	Extreme payer resistance — utilization management, quantity limits, prior authorization, step therapy; many commercial plans exclude GLP-1s for obesity indication; Medicare Part D coverage for obesity expanding under IRA
Prior authorization	Diagnosis-specific (T2DM vs. obesity have different coverage criteria); BMI documentation; prior therapy failure documentation; frequent renewal requirements
Hub services	Massive enrollment volumes; PA support at scale; copay assistance (critical given high patient cost-sharing); access navigation for different indications
Specialty pharmacy	Less specialized than oncology/rare — GLP-1s are relatively simple to dispense and store; primary challenge is supply management (shortages, demand spikes)
Clinical support	Weight management counseling, injection training, dose titration guidance, managing expectations on therapy duration
Time sensitivity	Moderate — weight management is not emergent, but patient motivation to start therapy is highest at point of prescriber conversation; delays cause abandonment

Vendor implications:

• Hub vendors must handle extreme enrollment volumes (semaglutide/tirzepatide are among the most prescribed specialty drugs by volume)
• PA automation is critical — AI PA vendors (Infinitus, Neon Health) are well-positioned for GLP-1 programs where PA volume is massive and criteria are relatively standardized
• Copay assistance programs face unique challenges: obesity indication often excluded from coverage, requiring manufacturer bridge programs
• Supply management (GLP-1 shortages have been persistent since 2023) creates operational complexity for specialty pharmacies
• The commercial model differs from traditional specialty: huge patient volumes, lower per-patient complexity, more price-sensitive patient population

5. Cell & Gene Therapy

Access complexity: Extreme

Dimension	C&GT-Specific Requirements
Administration	One-time dosing (gene therapy: IV infusion or intrathecal); cell therapy requires apheresis, manufacturing, and infusion (vein-to-vein chain); certified treatment centers
Reimbursement	Prices range from $500K to $3.5M per dose; medical benefit (hospital outpatient/inpatient); CMS NTAP (New Technology Add-on Payment) for inpatient; outcomes-based contracting emerging
Prior authorization	Extremely complex: genetic testing, clinical eligibility criteria, certified treatment center verification, insurance pre-authorization for high-cost single-episode therapy
Hub services	Patient identification, treatment center matching, complex PA management, financial counseling ($1M+ out-of-pocket without assistance), travel/lodging coordination, outcomes tracking
Specialty pharmacy	Ultra-cold storage (-80°C or cryogenic), chain-of-identity (cell therapy: patient cells must be tracked from collection through manufacturing to infusion), single-use vial logistics, REMS coordination
Clinical support	Pre-treatment conditioning regimen coordination, infusion center scheduling, post-infusion monitoring (cytokine release syndrome for CAR-T), long-term follow-up (15-year registries for gene therapy)
Time sensitivity	Extremely high for cell therapy (living product with limited shelf life); moderate for gene therapy (stable product once manufactured); manufacturing lead time 3-6 weeks for autologous cell therapy

Vendor implications:

• Very few hub vendors have validated C&GT capabilities — this is the most demanding therapeutic archetype
• CVS Specialty claims more gene therapy LDD launches than any other SP; Accredo has dedicated gene therapy infrastructure
• Independent SPs (PANTHERx) have invested in C&GT capabilities but market is still nascent
• Hub vendors must coordinate across treatment centers, specialty pharmacies, apheresis centers, and manufacturers — far more complex orchestration than standard hub workflows
• Outcomes-based contracting (annuity models, pay-for-performance) requires hub infrastructure for long-term patient tracking that most vendors don’t yet have
• 15-year registry requirements for gene therapy create a long-tail data management obligation

---

Vendor Selection Matrix by Therapeutic Area

Vendor	Oncology	Rare Disease	Autoimmune	GLP-1	C&GT
ConnectiveRx	Strong (B&B expertise)	Moderate	Strong (volume)	Moderate	Limited
EVERSANA	Strong	Moderate-Strong	Strong	Strong (volume)	Limited
AssistRx	Moderate	Moderate	Strong	Moderate	Limited
CareMetx (post Apr-2026 absorption of legacy Cencora/Lash hub)	Strong	Moderate	Strong	Strong	Moderate
McKesson/CoverMyMeds	Moderate (PA focus)	Moderate	Strong (PA)	Strong (PA)	Limited
CVS Specialty	Strong	Moderate	Strong	Moderate (supply)	Strong (LDD launches)
PANTHERx Rare	Limited	Best-in-class	Limited	N/A	Moderate
Accredo	Strong (15 TRCs)	Strong	Strong	Moderate	Strong
Phil	Limited	Limited	Moderate (copay)	Strong (digital)	N/A
Neon Health	Limited	Limited	Moderate	Strong (AI PA)	N/A

---

Cross-Cutting Capability Tests

Therapeutic-area specialization should be proven through workflow evidence, not just client logos. A vendor that says it supports oncology, rare disease, autoimmune, GLP-1, and CGT should be able to show how the operating model changes across at least five dimensions:

Capability test	What changes by therapeutic area
Benefit pathway	Oncology and infusion skew medical benefit; autoimmune and many GLP-1 programs skew pharmacy benefit; CGT can require both treatment-center and specialty-distribution workflows.
Case manager load	Rare disease and CGT require lower caseloads and deeper continuity; GLP-1 and autoimmune require volume automation.
Clinical credentialing	Oncology, CGT, rare disease, and infusion need specialized pharmacist, nurse, or MSL support; high-volume retail-specialty programs need efficient triage.
Data cadence	Rare disease and CGT need longitudinal, patient-level visibility; GLP-1 access programs need high-frequency PA / abandonment dashboards.
Network design	Oncology and rare disease often use LDDs; autoimmune is PBM/formulary driven; CGT is treatment-center and logistics driven.

These tests are especially important when a vendor cross-sells a general hub or SP platform into a new therapy class. The manufacturer should ask for live SOPs, sample case notes, KPI definitions, and exception-handling examples by therapy type rather than accepting a single enterprise capabilities deck.

Maturity Model

For each therapy archetype, classify the vendor’s experience into one of four maturity levels:

1. Claims only: Vendor has marketing language or adjacent experience but no named programs, SOPs, or therapy-specific metrics.
2. Workflow capable: Vendor can run the access or dispensing workflow, but relies on manufacturer-provided clinical design and external partners for exceptions.
3. Therapy-specialized: Vendor has dedicated staff, SOPs, payer-policy libraries, clinical escalation paths, data dashboards, and launch references in the therapy area.
4. Market-shaping: Vendor changes manufacturer strategy because it brings unique patient-finding, payer access, LDD, treatment-site, or longitudinal-data capability.

For first launches, the safest partner is usually maturity level 3 in the relevant therapy area. Level 4 can be valuable when the product is strategically complex, but it also creates dependency. Level 2 can work for low-complexity volume products if the manufacturer owns enough access strategy internally.

---

Key Takeaways

1. Match vendor selection to therapeutic archetype, not just company size. The largest hub vendor may not be the best for a rare disease launch requiring high-touch, low-caseload case management.
2. Oncology requires buy-and-bill expertise. Most hub vendors are optimized for pharmacy-benefit drugs. Provider-administered biologics have fundamentally different reimbursement workflows.
3. Rare disease requires specialized partners. PANTHERx’s thesis is correct: rare disease pharmacy is a different business than specialty pharmacy. The same principle applies to hub services.
4. GLP-1 demands volume and automation. The GLP-1 access crisis requires hub vendors that can handle massive enrollment volumes with PA automation — a different capability than clinical depth.
5. Cell & gene therapy is the frontier. Very few vendors have validated C&GT capabilities today. Manufacturers launching gene therapies should evaluate vendor readiness carefully and plan for custom infrastructure.
6. Biosimilar competition changes autoimmune vendor dynamics. Hub vendors supporting branded autoimmune products must increasingly help manufacturers with formulary defense and patient retention — not just initial access.

Implications

Manufacturers should build TA-specific RFP scorecards. Oncology should weight medical-benefit reimbursement, BCOP support, oral adherence, and site-of-care coordination. Rare disease should weight low-caseload case management, patient finding, caregiver support, and REMS/LDD execution. Autoimmune should weight biosimilar defense, accumulator exposure, refill adherence, and high-volume copay. GLP-1 should weight automation, retail/DTC routing, and payer-type segmentation. CGT should weight chain-of-identity, treatment-center orchestration, and long-term follow-up.

Pricing should also follow therapeutic complexity. A vendor that looks expensive on a per-patient basis may be appropriate for rare disease or CGT, while the same pricing model can be untenable for GLP-1 volume. Conversely, a low-cost digital vendor may fit high-volume metabolic access but under-serve oncology or rare disease escalation needs. Therapeutic-area proof should therefore sit ahead of generic platform demos.

---

Related Pages

• Hub Services Market Analysis
• Hub Services Buyer’s Guide 2026
• REMS & Limited Distribution Drug Networks
• Biosimilars & Impact on Pharma Services
• GLP-1 Dynamics
• Cell & Gene Therapy
• Patient Access Journey

Related Wiki Vendors (Auto)

Auto-generated cross-references closing audit-surfaced link gaps. Vendors named in the prose above without inline links are listed here so the wiki graph is queryable.

• AssistRx
• ConnectiveRx
• CoverMyMeds
• EVERSANA
• Neon Health
• Option Care Health
• PANTHERx Rare
• Phil